Rapyd Launches Stablecoin Payment Solutions: Digital Versatility Meets Dollar Stability
9.9.2025 14:00:00 CEST | Business Wire | Press release
Rapyd offers a single provider approach for stablecoin pay-ins and pay-outs, giving businesses an end-to-end solution in one integrated platform.What was once a fragmented, complex process is now unified, giving companies real-time liquidity and more control over cross-border payments.The fintech’s flexible settlement options and instant global payouts allow businesses to settle in stablecoins or send funds worldwide in seconds.
Rapyd, a leading global fintech company, today announced the launch of its Stablecoin Payment Solutions, giving businesses a secure and scalable way to accept stablecoins, settle in stablecoins and pay out using stablecoins.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250909572698/en/

Rapyd makes stablecoin payments seamless: Accept, settle, and pay out in one platform
2025 is the year stablecoins are moving from early-stage concept to real-world utility. Total volumes across blockchains surpassed $27 trillion1, surpassing the combined payment volumes of Visa and Mastercard in the same year2. That scale is beginning to reshape industries from gaming, to e-commerce, to traditional retail. Now, Rapyd is making it usable for enterprises in everyday payments and settlements.
Rapyd’s new suite of products addresses a central need for companies navigating volatile currencies, slow settlement times, and complex treasury operations. With Rapyd as a single provider, businesses can accept, settle, or send payouts instantly, eliminating the need for fragmented systems or multiple intermediaries. Businesses can now use Rapyd to:
- Accept Stablecoin Payments from global customers and instantly convert into preferred fiat currencies.
- Send Stablecoin Payouts securely to businesses and end users anywhere in the world, 24/7/365.
- Settle in Stablecoins to improve liquidity and reduce reliance on traditional rails like SWIFT or ACH.
“Stablecoins have moved from early-stage concept to global utility, and companies need partners who can bridge digital assets with real-world business needs,” said Arik Shtilman, CEO and Co-Founder of Rapyd. “Rapyd’s role is to strip away the complexity, integrate stablecoins into global money movement, and give businesses more control over how and when they move funds.”
The launch comes at a pivotal moment. New regulations in the US (GENIUS Act) and Europe (MiCA), along with similar initiatives in other major markets, are accelerating adoption by legitimizing stablecoins and setting clear operating standards. This regulatory clarity, combined with demand from industries such as gaming and online trading, is creating the most significant shift in financial infrastructure since the rise of card networks.
“Enterprises are under pressure to manage liquidity in real time while navigating multiple currencies and jurisdictions,” said David Rosa, General Manager of Rapyd’s Scale Business Unit. “Our Stablecoin Payment Solutions are built to remove those barriers. By combining stablecoin rails with our existing treasury, payout, and settlement infrastructure, we give CFOs and operations teams the ability to move funds instantly, reduce FX exposure, and cut out unnecessary intermediaries. It’s about taking what has been a fragmented, complex process and turning it into a single, reliable platform for global money movement.”
Rapyd’s end-to-end solution is designed for enterprises that need stability and speed in cross-border payments. For businesses operating globally, this means faster payouts. For platforms and marketplaces, it could reduce FX exposure. For the creator economy, it enables beneficiaries to receive payments with an instrument that is pegged to a currency value, even in emerging markets. By combining stablecoin rails with Rapyd’s existing global payments network, the company is positioning itself as the single provider for businesses seeking flexibility in both fiat and digital currencies.
For more information, visit: rapyd.net/solutions/stablecoin-payments
About Rapyd
Rapyd lets you build bold. Liberate global commerce with all the tools your business needs to create payment, payout and fintech experiences everywhere. From Fortune 500s to ambitious business and technology upstarts, our payments network and powerful fintech platform make it easy to pay suppliers and get paid by customers—locally or internationally.
With offices worldwide, including London, Tel Aviv, Dubai, Iceland, Amsterdam, San Francisco, Miami, Hong Kong and Singapore, we know what it takes to make cross-border commerce as easy as being next door. Rapyd simplifies payments so you can focus on building your business.
Get the tools to grow globally and learn about our products, solutions and partner programmes at www.rapyd.net. Follow: Blog, Insta, LinkedIn, Twitter.
1 Coin Telegraphcointelegraph.com/news/stablecoins-beat-visa-mastercard-2024-volume
2 CCN
Disclaimer
Rapyd’s stablecoin-related services are enabled through partnerships with regulated third-party providers. Rapyd does not itself issue, custody, or directly process crypto assets. All crypto-related services are subject to the terms, conditions, and regulatory status of Rapyd’s third-party partners. These services are delivered in collaboration with trusted third-party providers, ensuring compliance and security across all stablecoin transactions. Rapyd works with partners that adhere to applicable regulatory requirements in each jurisdiction. This Press Release is not an invitation or inducement to engage in investment activity, and does not seek to promote any such services or similar activities.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250909572698/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom